POM-V Prescription Required Companion Animal

Arthrocam 0.5 mg/ml Oral Suspension for Cats

Active ingredient: Meloxicam

Form

Liquid

Species

Cats

Manufacturer

Chanelle Pharmaceuticals Manufacturing Ltd

VMD MA No.

08749/3124

What it's used for

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Allev...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Arthrocam 0.5 mg/ml Oral Suspension for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Alleviation of mild to moderate post-operative pain and inflammation following
surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders
in cats.

Oral use.
Post-operative pain and inflammation following surgical procedures:
After initial treatment with a suitable 5 mg/ml meloxicam solution for injection for cats,
continue treatment 24 hours later with Arthrocam 0.5 mg/ml oral suspension for cats
at a dosage of 0.05 mg meloxicam/kg body weight (0.1 ml /kg). The oral follow-up
dose may be administered once daily (at 24-hour intervals) for up to four days.
Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight (0.4 ml/kg)
on the first day. Treatment is to be continued once daily by oral administration (at 24-
hour intervals) at a dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg) for as
long as acute pain and inflammation persist.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight (0.2 ml/kg)
on the first day. Treatment is to be continued once daily by oral administration (at 24-
hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight (0.1 ml
/kg). A clinical response is normally seen within 7 days. Treatment should be
discontinued after 14 days at the latest if no clinical improvement is apparent.

Revised: November 2025
AN: 02292/2025
Route and method of administration
A one ml syringe is provided with the product. To be administered orally either mixed
with food or directly into the mouth. Particular care should be taken with regard to the
accuracy of dosing. The recommended dose should not be exceeded.
Advice on correct administration
Shake well before use.
Avoid introduction of contamination during use.

Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in known cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cats less than 6 weeks of age.

Revised: November 2025
AN: 02292/2025

Cats:
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Appetite loss*, Lethargy*
Renal failure*
Vomiting*, Diarrhoea*, Blood in faeces*, Gastrointestinal
ulceration
Elevated liver enzymes
* Typical adverse reactions of NSAIDs
These side effects are in most cases transient and disappear following termination of
the treatment but in very rare cases may be serious or fatal.

Revised: November 2025
AN: 02292/2025
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder, or the national competent authority via the
national reporting system. See also section 16 of the package leaflet for contact
details.

None.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
Post-operative use:
In case additional pain relief is required, multimodal pain therapy should be
considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a
veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to non-steroidal anti-Inflammatory drugs
(NSAIDs) should avoid contact with the veterinary medicinal product. Accidental
ingestion of the product by a child may cause gastro-intestinal effects, such as
nausea and gastric pain.
Any uneaten medicated food must be disposed of immediately and the bowl washed
thoroughly.
Do not leave an unattended filled syringe in the sight or reach of children.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes, immediately
rinse thoroughly with water.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Arthrocam must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should
be avoided.
In cats, pre-treatment with anti-inflammatory substances may result in additional or
increased adverse effects and accordingly a treatment-free period with such
veterinary medicinal products should be observed for at least 24 hours before
commencement of treatment. The treatment-free period, however, should take into
account the pharmacological properties of the products used previously.

This veterinary medicinal product does not require any special storage conditions.

Revised: November 2025
AN: 02292/2025

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.